Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

Abstract Background β-amyloid (Aβ) positron emission tomography (PET) imaging is currently the only Food and Drug Administration-approved method to support clinical diagnosis of Alzheimer’s disease (AD). However, numerous research studies support the use of cerebrospinal fluid (CSF) biomarkers, as a...

Full description

Bibliographic Details
Main Authors: James D. Doecke, Larry Ward, Samantha C. Burnham, Victor L. Villemagne, Qiao-Xin Li, Steven Collins, Christopher J. Fowler, Ekaterina Manuilova, Monika Widmann, Stephanie R. Rainey-Smith, Ralph N. Martins, Colin L. Masters, the AIBL Research Group
Format: Article
Language:English
Published: BMC 2020-03-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer’s disease
Beta-amyloid
Cerebrospinal fluid
Concordance PET
Tau
Online Access:http://link.springer.com/article/10.1186/s13195-020-00595-5

Internet

http://link.springer.com/article/10.1186/s13195-020-00595-5

Similar Items